Insulet (Insulet) Interest Expense

: $-34 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Insulet's interest expense for the three months ended in Dec. 2023 was $ -7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-34 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Insulet's Operating Income for the three months ended in Dec. 2023 was $ 106 Mil. Insulet's Interest Expense for the three months ended in Dec. 2023 was $ -7 Mil. Insulet's Interest Coverage for the quarter that ended in Dec. 2023 was 15.88. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Insulet Interest Expense Historical Data

The historical data trend for Insulet's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-31.80

-45.20

-61.70

-36.00

-36.20

Insulet Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-8.70	-8.30	-8.50	-10.40	-6.70

Insulet Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34 Mil.

Insulet (NAS:PODD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Insulet's Interest Expense for the three months ended in Dec. 2023 was $-7 Mil. Its Operating Income for the three months ended in Dec. 2023 was $106 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1,366 Mil.

Insulet's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	106.4	/	-6.7
	=	15.88

The higher the ratio, the stronger the company's financial strength is.

Insulet (Insulet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

PODD:Mexico GOV:Germany GOV:Germany

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Executives

Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic	officer: CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh	officer: SVP, Global Operations	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead	director	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan	officer: EVP, CFO	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field	officer: SVP & Chief Technology Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea	officer: SVP, Chief HR Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue	director	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin	officer: SVP, Reg, Quality & Compliance	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche	officer: SVP, Global Manufacturing	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen	officer: SVP and CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears	officer: SVP, Quality and Regulatory	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine	director	C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford	director	C/O HOLOGIC, INC., BEDFORD MA 01730